Quick Takeaways
- This page summarizes Sameer Dewan's Form 4 filing for Genpact LTD (G).
- 2 reported transactions and 0 derivative rows are listed below.
- Filing timestamp: 13 Jan 2026, 21:35.
Sameer Dewan - 10 Jan 2026 Form 4 Insider Report for Genpact LTD (G)
- Signature
- /s/ Thomas D. Scholtes, as Attorney-in-fact for Sameer Dewan
- Issuer symbol
- G
- Transactions as of
- 10 Jan 2026
- Net transactions value
- -$1,175,642
- Form type
- 4
- Filing time
- 13 Jan 2026, 21:35:07 UTC
- Previous filing
- 13 Nov 2025
- Next filing
- 03 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Sameer Dewan filed Form 4 for Genpact LTD (G) on 13 Jan 2026."
What Changed
- Previous filing in this sequence was filed on 13 Nov 2025.
- Current net transaction value: -$1,175,642.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dewan Sameer | Senior Vice President | C/O GENPACT LLC, 521 FIFTH AVENUE, 14TH FLOOR, NEW YORK | /s/ Thomas D. Scholtes, as Attorney-in-fact for Sameer Dewan | 13 Jan 2026 | 0002015050 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | G | Common Shares | Tax liability | $471,787 | -9,780 | -16% | $48.24 | 52,837 | 10 Jan 2026 | Direct | F1 |
| transaction | G | Common Shares | Sale | $703,855 | -15,088 | -29% | $46.65 | 37,749 | 13 Jan 2026 | Direct | F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents shares withheld for payment of taxes upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan and exempt under Rule 16b-3. |
| F2 | The sales transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
| F3 | The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $46.40 to $47.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |